American Journal of Physiology-Heart and Circulatory Physiology · 2023 · 14 citations · 48 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyCellular PharmacologyRegenerative MedicineDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyHeart FailureSodium-glucose Cotransporter 2 InhibitorsCardiovascular FailurePeripheral Blood Stem CellsPrimitive CellsProgenitor CellsSodium-glucose Cotransporter 2 Inhibition
Using an aldehyde dehydrogenase (ALDH) activity-based flow cytometry assay, we found that empagliflozin treatment for 6 mo was associated with parallel increases in circulating vascular regenerative ALDH hi -CD34/CD133-coexpressing progenitors and decreased proinflammatory ALDH hi -CD14/CD86-coexpressing monocyte precursors in individuals without diabetes but with cardiovascular risk factors. The rejuvenation of the vascular regenerative cell reservoir may represent a mechanism via which sodium glucose-cotransporter 2 (SGLT2) inhibitors limit maladaptive repair and delay the development and progression of cardiovascular diseases.
48
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler et al. · New England Journal of Medicine · 2020 · 5K citations · Full text
Medicine, Cardiology, Pharmacology +17
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker, Javed Butler, Gerasimos Filippatos et al. · New England Journal of Medicine · 2021 · 4.6K citations · Full text
Medicine, Cardiology, Pharmacology +14